Group 1: Company Overview and Strategic Partnerships - The company has established a strategic partnership with Defo Capital, aiming to become a major platform for integrating past investment businesses in the health sector, with a goal of "building China's DSM" [2][3] - The collaboration with DSM-Firmenich has been ongoing since 2024, focusing on achieving annual procurement targets and strengthening revenue foundations through mutual trust and business empowerment [4][5] Group 2: Product Development and Innovations - The company has developed a synthetic biology business strategy since 2022, focusing on enhancing production efficiency and reducing costs, with key products including the steviol glycoside RM series and biopolysaccharides [3][4] - The steviol glycoside RM2 product received FDA GRAS certification last year, with domestic certification pending final review, highlighting its advantages in sweetness, taste, solubility, and cost control [3] - Biopolysaccharides have been industrialized and are currently applied in the daily chemical sector, with ongoing efforts to obtain relevant certifications [3] Group 3: Manufacturing and Operational Enhancements - The company has upgraded its Indiana plant to a comprehensive plant extraction facility, focusing on brand raw materials and ensuring local resource utilization to enhance market competitiveness [5][6] - Future capital expenditures are expected to be minimal as the company shifts focus to operational efficiency and market expansion, particularly in the stevia extraction and synthetic biology sectors [6] Group 4: Market Trends and Regulatory Environment - Over 100 countries have implemented sugar tax policies, indicating a global trend towards health consciousness and diabetes management, which may positively impact the company's natural sweetener business [7] - The company is monitoring developments in the CBD market, with recent positive signals from U.S. policies regarding CBD inclusion in healthcare plans, while emphasizing the need for clear regulatory standards [7]

Core Viewpoint - The company is undergoing a change in control and asset acquisition, aiming for vertical integration of its supply chain through the acquisition of 95.5% of Beijing Jinkangpu's shares [1][2]. Group 1: Control Change and Management - The company plans to resume trading on December 24, 2025, and will initiate a control change and a comprehensive transaction plan [2]. - The original controlling shareholder intends to transfer 8.09% of shares and relinquish voting rights for 25.5% of shares, with Guangzhou Defu Nutrition Investment Partnership becoming the new controlling shareholder [2]. - As of February 10, 2026, the share transfer agreement and asset audit are progressing as planned, with the company committing to disclose updates every 30 days [2]. Group 2: Project Advancement - The acquisition is aimed at downstream vertical integration, focusing on synergy in technology, market, and raw materials [3]. - Beijing Jinkangpu possesses advantages in formula development and customer networks, which may enhance the company's application solution capabilities and customer loyalty post-acquisition [3]. - The effectiveness of the integration and the pace of business expansion will be key areas for long-term observation [3]. Group 3: Strategic Development - The company will continue to focus on high-quality market targets around its core business of natural health ingredients, considering both horizontal and vertical integration opportunities [4]. - The resources from Defu Capital may facilitate the company's transformation from a raw material supplier to a platform enterprise, potentially leading to governance optimization and resource integration [4]. Group 4: Capacity Expansion - The company has completed global capacity layout, but the new factories have a short operational history, resulting in low current capacity utilization [5]. - Future capacity release will depend on sales growth of core products, expansion into new categories, and the rollout of synthetic biology technology products [5].

Core Viewpoint - The collaboration between Rhein Biotech and Defo Capital is driven by a shared vision for the natural health ingredients sector and mutual recognition of strategic alignment [1] Group 1: Strategic Alignment - Both Defo Capital and Rhein Biotech have a strong belief in the potential of the natural health ingredients niche, which forms the foundation for their partnership [1] - The strategic alignment and shared philosophy between the two entities are key drivers for the collaboration [1] Group 2: Comprehensive Advantages - Rhein Biotech has over 20 years of industry experience, which contributes to its strong market position and comprehensive advantages that Defo Capital considered [1] - The company has a well-established industrial layout, sufficient production capacity, leading production technology, and a robust quality control system [1] - Rhein Biotech's global sales network and solid governance structure provide a strong foundation for its development [1] Group 3: Product Development Capabilities - The company possesses systematic capabilities in product selection, expansion, and incubation, supported by a complete R&D and industrialization chain [1] - This capability allows for efficient transformation of products from concept to market [1] Group 4: Technological Advancement - Rhein Biotech demonstrates a strong internal drive for business upgrades and technological iteration, maintaining a keen awareness of technological advancements [1] - The company has proactively engaged in cutting-edge fields such as synthetic biology and formulation applications, successfully achieving technological upgrades [1] - Rhein Biotech is actively exploring diverse application scenarios, including animal feed and pet nutrition, showcasing its growth potential and vitality [1]

Core Viewpoint - The collaboration between Rhein Biotech and Defo Capital is driven by a shared strategic vision and mutual recognition of the potential in the natural health ingredients sector [1] Group 1: Strategic Alignment - Both Defo Capital and Rhein Biotech have a strong belief in the natural health ingredients niche, which forms the foundation of their partnership [1] - The strategic alignment and shared philosophy between the two entities are key drivers for the collaboration [1] Group 2: Comprehensive Advantages - Rhein Biotech has over 20 years of industry experience, establishing a solid industry position and comprehensive advantages that attracted Defo Capital [1] - The company boasts a well-rounded industrial layout, robust production capacity, leading production technology, and a global sales network, ensuring a strong operational foundation [1] - Rhein Biotech possesses systematic capabilities in product selection, development, and incubation, enabling efficient transformation from concept to market [1] Group 3: Continuous Business Upgrades - The company demonstrates an internal drive for continuous business upgrades and technological iterations, maintaining a keen awareness of technological advancements [1] - Rhein Biotech has proactively ventured into cutting-edge fields such as synthetic biology and formulation applications, successfully achieving technological upgrades [1] - The company is actively exploring diverse application scenarios, including animal feed and pet nutrition, showcasing its growth vitality and potential [1]